Launching a New Polymer for Controlled Release: Challenges, De-risking, and Breaking Through Historical Precedent
Monday, July 26th - 12pm (Noon) EDT
|
Sponsored By:
|
|
As long-acting implant technology for sustained drug delivery gains traction in the pharmaceutical industry, developers of novel polymer technologies must be prepared to navigate the long road to commercialization.
Secant Group is travelling that road with the development of Hydralese™ (PGSU), a highly tunable biocompatible elastomer for combination drug delivery devices, that demonstrates multi-month release of a variety of therapeutic drugs via surface erosion, with the potential for drug therapy lasting longer than 1 year. As a controlled release platform with many advantages over polymers currently on the market, Hydralese can be manufactured into a variety of forms, such as implants, microspheres, and coatings.
Commercializing novel polymer technologies for controlled release—even those with clear benefits—is a journey lined with hurdles. However, they can be overcome with the right approach.
This session will address:
Secant Group is travelling that road with the development of Hydralese™ (PGSU), a highly tunable biocompatible elastomer for combination drug delivery devices, that demonstrates multi-month release of a variety of therapeutic drugs via surface erosion, with the potential for drug therapy lasting longer than 1 year. As a controlled release platform with many advantages over polymers currently on the market, Hydralese can be manufactured into a variety of forms, such as implants, microspheres, and coatings.
Commercializing novel polymer technologies for controlled release—even those with clear benefits—is a journey lined with hurdles. However, they can be overcome with the right approach.
This session will address:
- the current state of controlled release polymers on the market
- the datasets needed to de-risk a new excipient for use by pharmaceutical formulators
- the gaps between academic innovation and industry adoption
- how to bring better next-generation drug delivery solutions to patients
Speaker
Dr. Stephanie Reed
Secant Group, Director, Translational Product Development
Dr. Stephanie Reed
Secant Group, Director, Translational Product Development
Stephanie Reed, PhD, is the Director of Translational Product Development at Secant Group, a textiles and biomaterials company outside of Philadelphia. At Secant Group, Dr. Reed leads a team of scientists whose goal is to launch new biomaterial polymers for commercial use in controlled release drug products, biomedical devices, and tissue engineering applications. Dr. Reed garners 14-plus years of experience in drug delivery, biomaterials, 3D printing technologies, regulatory submission, and product commercialization. Dr. Reed earned a BS in Mechanical Engineering at Massachusetts Institute of Technology, and an MS and PhD in Biomedical Engineering at University of California Los Angeles.
